Nanobio and Nanomedicine

A nanotechnology company devoted to developing, and commercializing the Personal Laboratory System™, a lab-on-a-chip analysis platform for droplet-based ('digital') microfluidics.

The company is developing a novel immunotherapy for cancer. It uses synthetic shells of Polyoma viruses as transportation vehicles for active agents vaccines.

Rexahn and the University of Maryland, Baltimore (UMB) Center for Nanomedicine & Cellular Delivery (CNCD), are jointly pursuing the development of water-soluble nano-polymers for targeted delivery of anticancer drugs.

RXi Pharmaceuticals is a discovery-stage biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi) for the treatment of serious human diseases. The company has developed novel and proprietary nanotransporters that have been shown to deliver RNAi compounds to target tissues in animal models.